首页|玻璃体切割手术联合地塞米松玻璃体腔植入剂治疗增生型糖尿病视网膜病变的疗效观察

玻璃体切割手术联合地塞米松玻璃体腔植入剂治疗增生型糖尿病视网膜病变的疗效观察

扫码查看
目的 观察玻璃体切割手术(PPV)联合地塞米松玻璃体腔植入剂(DEX)治疗增生型糖尿病视网膜病变(PDR)的临床疗效。方法 前瞻性随机对照研究。2021年5月至2023年2月于南京医科大学第一附属医院眼科检查确诊的PDR患者57例79只眼纳入研究。患眼均行最佳矫正视力(BCVA)、光相干断层扫描(OCT)检查。采用OCT仪测量黄斑中心凹视网膜厚度(CMT)。随机将患者分为对照组、试验组,分别为27例35只眼、30例44只眼。患眼均行常规25GPPV、手术中全视网膜激光光凝治疗。手术完毕时,试验组给予玻璃体腔注射0。7mgDEX。手术后1、4、12、24周采用手术前相同设备和方法行相关检查。按照DR严重程度评分(DRSS)对患眼手术后改善情况进行评估。两组间以及组内手术前后logMARBCVA、CMT比较采用混合方差分析。结果 手术后1、4、12、24周时,两组患眼手术后不同时间点BCVA均较手术前有明显改善,差异均有统计学意义(P<0。001)。手术后不同时间,试验组患眼BCVA、CMT均显著优于对照组,差异均有统计学意义(P<0。05)。与手术前CMT比较,试验组患眼手术后不时间点CMT均明显下降,差异有统计学意义(P<0。05);对照组患眼手术后1周,差异无统计学意义(P=0。315);手术后4、12、24周,CMT降低,差异均有统计学意义(P<0。05)。与手术前比较,手术后1、4、12、24周DRSS提升两阶以上者,试验组分别为20(45。45%,20/44)、26(59。10%,26/44)、32(72。73%,32/44)、31(70。45%,31/44)只眼;对照组分别为 15(42。86%,15/35)、15(42。86%,15/35)、16(45。71%,16/35)、18(51。43%,18/35)只眼。对照组、试验组手术后不同时间DRSS较手术前提升两阶以上者比较,手术后1、4、24周,差异无统计学意义(P=0。817、0。178、0。105);手术后12周,差异有统计学意义(P=0。020)。结论 PPV联合手术中玻璃体腔注射DEX治疗PDR,能提高患者手术后视力,减轻手术后黄斑水肿,改善DR严重程度。
Efficacy of pars plana vitrectomy combined with intravitreal dexamethasone for proliferative diabetic retinopathy
Objective To observe the clinical efficacy of pars plana vitrectomy(PPV)combined with dexamethasone intravitreal implant(DEX)in the treatment of proliferative diabetic retinopathy(PDR).Methods A prospective randomized controlled study.A total of 57 PDR patients with 79 eyes diagnosed by Department of Ophthalmology of The First Affiliated Hospital of Nanjing Medical University from May 2021 to February 2023 were included in the study.Best corrected visual acuity(BCVA)and optical coherence tomography(OCT)were performed in all affected eyes.Central macular thickness(CMT)was measured by OCT.The patients were randomly divided into control group and experimental group,with 27 cases and 35 eyes and 30 cases and 44 eyes,respectively.All eyes were treated with routine 25G PPV and intraoperative whole-retina laser photocoagulation.At the end of the operation,the experimental group was given 0.7 mg DEX intravitreal injection.At 1,4,12,and 24 weeks after operation,the same equipment and methods were used for relevant examinations.The improvement after surgery was assessed according to the diabetic retinopathy severity score(DRSS).Mixed analysis of variance was used to compare logarithm of the minimum angle of resolution BCVA and CMT between the two groups and within the two groups before and after operation.Results At 1,4,12 and 24 weeks after surgery,BCVA was significantly improved at different time points after surgery,and the differences were statistically significant(P<0.001).At different time after operation,BCVA and CMT in experimental groups were significantly better than that in control group,with statistical significance(P<0.05).Compared with the CMT before surgery,the CMT at all time point after surgery in experimental group were significantly decreased,and the difference were statistically significant(P<0.05).There was no significant difference one week after eye operation in control group(P=0.315).At 4,12 and 24 weeks after operation,CMT decreased in control group,and the differences were statistically significant(P<0.05).Compared with before surgery,DRSS increased two steps higher at 1,4,12 and 24 weeks after surgery in 20(45.45%,20/44),26(59.10%,26/44),32(72.73%,32/44)and 31(70.45%,31/44)eyes in the experimental groups,respectively.The control group consisted of 15(42.86%,15/35),15(42.86%,15/35),16(45.71%,16/35)and 18(51.43%,18/35)eyes,respectively.There was no significant difference in DRSS at 1,4 and 24 weeks after operation between the control group and the experimental group(P=0.817,0.178,0.105).At 12 weeks after surgery,the difference was statistically significant(P=0.020).Conclusion PPV combined with intravitreal injection of DEX in the treatment of PDR can improve postoperative visual acuity,alleviate postoperative macular edema and improve the severity of DR.

Proliferative diabetic retinopathyIntravitreal dexamethasone implantPars plana vitrectomy

邱奥望、俞灏、刘庆淮、张薇玮

展开 >

南京医科大学第一附属医院眼科,南京 210029

增生型糖尿病视网膜病变 地塞米松玻璃体腔植入剂 玻璃体切除术

国家自然科学基金青年项目江苏省科技厅重点研发计划社会发展项目

81900873BE2023777

2024

中华眼底病杂志
中华医学会

中华眼底病杂志

CSTPCD北大核心
影响因子:0.928
ISSN:1005-1015
年,卷(期):2024.40(6)